“Every day we get more requests from investors who want to know more about the topic and how to work with us," Damiano said, highlighting the impact of the Foundation's Access to Medicine Index Statement, as well as the Investor Action on Antimicrobial Resistance Initiative.
The article is published as part of Sustainable Views at esg-specialist.com, which is the Financial Times's new prototype publication aimed at financial services professionals. This "aims to be the authoritative source of information on developments in sustainability policy and regulation, the impact of environmental, social and governance factors on capital markets, and the transition to a green and just economy."
The article outlines examples of how investors have pressed for, and achieved, progress on global access issues at some of the world's largest pharmaceutical companies.
Damiano told the publication that investor coalitions and groups have now reached critical scale, saying: "This is why it’s great for us to have more than 100 investors, more that $20tn, because when our investors speak to companies they come with a sizeable ownership of the company."
Read the full article on the Sustainable Views website.